304
Participants
Start Date
August 31, 2014
Primary Completion Date
March 31, 2015
Study Completion Date
March 31, 2015
LY2623091
Administered orally
Tadalafil
Administered orally
Spironolactone
Administered orally
Placebo
Administered orally
Rochester Clinical Research, Inc., Rochester
PharmQuest, Greensboro
Metrolina Internal Medicine, P.A., Charlotte
Mountain View Clinical Research, Inc, Greer
Jacksonville Center for Clinical Research, Jacksonville
Avail Clinical Research LLC, DeLand
Alan Graff, MD, PA, Fort Lauderdale
Cardiovascular Center of Sarasota, Sarasota
Columbus Clinical Research, Columbus
Rapid Medical Research Inc, Cleveland
Sterling Research Group, LTD, Cincinnati
Dayton Clinical Research, Dayton
Midwest Institute for Clinical Research, Indianapolis
Community Clinical Research Center, Muncie
Lillestol Research LLC, Fargo
Northwest Heart Clinical Research, LLC, Arlington Heights
Cedar-Crosse Research Center, Chicago
Heartland Research Associates, Wichita
Grace Research, Bossier City
Oklahoma Foundation For Cardiovascular Research, Oklahoma City
Texas Diabetes and Endocrinology, P.A., Round Rock
Tekton Research, Inc, Austin
Rocky Mountain Diabetes and Osteoporosis Center, Idaho Falls
Clinical Research Advantage, Glendale
AB Clinical Trials, Las Vegas
Encompass Clinical Research, Encinitas
John Muir Health Network - The Osteoporosis Center, Concord
East West Medical Institute, Honolulu
Universal Research Group, LLC, Tacoma
Cor Clinical Research LLC, Oklahoma City
Maine Research Associates, Auburn
Texas Diabetes and Endocrinology, Austin
Northwest Clinical Research Center, Bellevue
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Brampton
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kelowna
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Peterborough
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pointe-Claire
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Québec
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Red Deer
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sherbrooke
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toronto
Research and Cardiovascular Corp., Ponce
Clinical Research Puerto Rico, Inc., San Juan
Eli Lilly and Company
INDUSTRY